Cellular Therapy
Conference Coverage
Adding rituximab to reduced intensity conditioning boosts PFS
ORLANDO – Rituximab conferred a significant progression-free survival benefit in reduced intensity conditioning regimens for patients with B-cell...
Conference Coverage
Follistatin, endoglin predict postallogeneic HCT NRM
ORLANDO – Follistatin and endoglin levels at posttransplant day 28 predict 1-year nonrelapse mortality in patients who have undergone...
From the Journals
MDS gene mutations predict response to HSCT
Genetic mutations in blood samples may predict outcomes and guide treatment for patients of all ages who have myelodysplastic syndrome and are...
From the Journals
Palliative care improves quality of life after HCT
Inpatient palliative care can help maintain quality of life in patients undergoing hematopoietic stem cell transplantation.
Conference Coverage
VIDEO: Despite toxicities, ibrutinib is beneficial for treatment-resistant graft-vs.-host disease
SAN DIEGO – An oral regimen of 420 mg ibrutinib achieved complete response in one-third of allogeneic stem cell recipients with chronic graft-vs.-...
Conference Coverage
Bone marrow cells prove limb-saving for some
NEW ORLEANS – Treatment with autologous bone marrow cells can avert amputation in selected patients who have critical limb ischemia and are not...
Conference Coverage
Myeloablative HSCT bests IV CYC for systemic scleroderma
WASHINGTON – Myeloablative autologous hematopoietic stem cell transplantation showed long-term superiority over monthly intravenous...
From the Journals
Worse outcomes for double-hit lymphomas after ASCT
Patients with double-hit lymphomas and double-expressor lymphomas have inferior outcomes after undergoing autologous stem cell transplantation,...
Conference Coverage
Allogeneic stem cells show promise for treating nonischemic dilated cardiomyopathy
NEW ORLEANS – Allogeneic stem cells appear to be a safe treatment option for nonischemic dilated cardiomyopathy and show somewhat greater efficacy...
Conference Coverage
Lenalidomide maintenance prolongs overall survival after ASCT
Lenalidomide maintenance therapy significantly prolonged overall survival after autologous stem cell transplant in newly diagnosed multiple...
News
Donor EBV status affects recipient graft-vs-host disease risk
Key clinical point: In allogeneic hematopoietic stem-cell transplantation, the donor’s EBV status affects the recipient’s risk of developing GVHD...